Related Experiment Videos

The influence of complement receptor type 1 (CD35) and decay-accelerating factor (CD55) on complement receptor type

R G Leslie1

  • 1Department of Immunology & Microbiology, Institute of Medical Biology, University of Southern Denmark, Denmark.

Immunology
|August 14, 1999
PubMed

Insights

Complement receptor type 1 (CR1) remodels C3b fragments on B cells, enabling complement receptor type 2 (CR2) to activate the alternative pathway. Decay-accelerating factor (DAF) does not hinder this process.

Area of Science:

  • Immunology
  • Complement System Biology

Background:

  • The complement system is crucial for innate and adaptive immunity.
  • Complement receptor type 2 (CR2) plays a role in B cell activation.
  • CR2-mediated complement activation is essential for B cell function.

Purpose of the Study:

  • To investigate the role of complement receptor type 1 (CR1) and decay-accelerating factor (DAF) in CR2-mediated alternative pathway (AP) activation on B cells.
  • To elucidate the mechanisms by which CR1 and DAF modulate complement activation on B cells.

Main Methods:

  • Assessing the influence of CR1 and DAF on CR2-mediated AP activation.
  • Analyzing the formation and function of the AP convertase on CR2.
  • Investigating the remodelling of C3b fragments by CR1.

Main Results:

  • Neither DAF nor CR1 impede the function of the AP convertase formed on CR2.
  • CR1 significantly remodels C3b fragments at secondary acceptor sites on B cells.
  • Remodelled C3b fragments become suitable ligands for CR2.

Conclusions:

  • CR1 is essential for effective CR2-mediated AP activation by modifying C3b deposition.
  • DAF does not inhibit CR2-mediated AP activation.
  • These findings highlight a novel regulatory mechanism in B cell complement activation.

Related Concept Videos